Get the Stockscreener App
60.55
14.61%
7.72
Pre-market:
58.90
-1.65
-2.73%
Anaptysbio Inc stock is traded at $60.55, with a volume of 1.10M.
It is up +14.61% in the last 24 hours and up +25.16% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$52.83
Open:
$56.08
24h Volume:
1.10M
Relative Volume:
2.43
Market Cap:
$1.68B
Revenue:
$169.47M
Net Income/Loss:
$-84.63M
P/E Ratio:
-21.48
EPS:
-2.8189
Net Cash Flow:
$-145.42M
1W Performance:
+9.87%
1M Performance:
+25.16%
6M Performance:
+187.10%
1Y Performance:
+297.05%
1-Day Range:
$54.17
$62.69
1-Week Range:
$52.68
$62.69
52-Week Range:
$15.12
$62.69
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
60.55 | 1.46B | 169.47M | -84.63M | -145.42M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Canada
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - simplywall.st
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - Yahoo Finance
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com
AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat
H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada
Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com
AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq
HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Mil - GuruFocus
AnaptysBio earnings beat by $0.71, revenue topped estimates - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
AnaptysBio Q4 Swings to Profit, Revenue Rises - marketscreener.com
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan - TradingView
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 71c - StreetInsider
Anaptysbio 10-K: $234.6M Revenue, $(0.46) EPS - TradingView
Planned AnaptysBio (NASDAQ: ANAB) split separates royalties from pipeline - Stock Titan
AnaptysBio, Inc. Announces Spin-off of Biopharma Operations to Form First Tracks Biotherapeutics, Targeting Q2 2026 - Quiver Quantitative
Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q4 Revenue $108.2M, vs. FactSet Est of $87.0M - marketscreener.com
AnaptysBio (NASDAQ: ANAB) Q4 profit, royalties surge and 2026 spin-off - Stock Titan
Commit To Buy AnaptysBio At $35, Earn 15.9% Annualized Using Options - Nasdaq
ANAB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ANAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AnaptysBio, Inc. (ANAB) Stock Analysis: A Biotech With 21% Potential Upside - DirectorsTalk Interviews
FDA accepts Vanda’s imsidolimab application for rare skin disorder - Investing.com
FDA accepts Vanda’s imsidolimab application for rare skin disorder By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - ChartMill
AnaptysBio stock hits 52-week high at $57.73 By Investing.com - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $57.73 - Investing.com
Big Picture: Can AnaptysBio Inc grow without external fundingWeekly Trade Review & Proven Capital Preservation Tips - baoquankhu1.vn
How Anaptysbio Inc. (ANAB) Affects Rotational Strategy Timing - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $4.45 Million Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. (ANAB) Investor Outlook: Analyzing a 22.46% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
AnaptysBio (ANAB) to Release Quarterly Earnings on Thursday - Defense World
AnaptysBio, Inc. $ANAB Stock Holdings Trimmed by GSA Capital Partners LLP - MarketBeat
ANAB PE Ratio & Valuation, Is ANAB Overvalued - Intellectia AI
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat
AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors - DirectorsTalk Interviews
AnaptysBio Insider Sells $540,000 in Stock - National Today
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - MarketBeat
Page not foundAirwhon - MarketBeat
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Feb 11 '26 |
Sale |
54.00 |
10,000 |
540,000 |
12,835 |
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):